SAN DIEGO, Aug. 1, 2016 /PRNewswire/ -- Arena
Pharmaceuticals, Inc. (NASDAQ: ARNA), today announced that the
Company will release its second quarter 2016 financial results and
provide a corporate update on Monday, August
8, 2016, after the close of the U.S. financial
markets. The Company will host a conference call and live
webcast with the investment community on Monday, August 8, 2016 at 4:30 p.m. ET to discuss the financial results and
provide a corporate update.
Conference Call & Webcast Information
When:
August 8, 2016, 4:30 p.m. ET
Dial-in: (877) 643-7155 (United
States) or (914) 495-8552 (International)
Conference ID: Arena Pharmaceuticals Second Quarter 2016 Conference
Call
Please join the conference call at least 10 minutes early to
register.
You can access the live webcast under the investor relations
section of Arena's website at: www.arenapharma.com.
A replay of the conference call will be archived under the
investor relations section of Arena's website at www.arenapharm.com
for 30 days shortly after the call.
About Arena Pharmaceuticals
We are a biopharmaceutical
company focused on developing novel, small molecule drugs across a
range of therapeutic areas. We have three primary proprietary
clinical programs: etrasimod (APD334) in Phase 2 evaluation for
ulcerative colitis; ralinepag (APD811) in Phase 2 evaluation for
pulmonary arterial hypertension (PAH); and, APD371 which has
completed Phase 1 testing. Additionally, we have
collaborations with four pharmaceutical companies: Eisai Ltd. and
Eisai Inc. (commercial stage); Axovant Sciences Ltd. (Phase 2
candidate); Ildong Pharmaceuticals Co., Ltd (Phase 1 candidate);
and, Boehringer Ingelheim International GmbH (preclinical
candidate).
Our US operations are located in San
Diego, California. Our primary clinical operations are
located in Zug, Switzerland, and
our commercial manufacturing for BELVIQ is located in Zofingen,
Switzerland.
Forward Looking Statements
Certain statements in this
press release are forward-looking statements that involve a number
of risks and uncertainties. Such forward-looking statements include
statements about Arena's focus, plans and strategy; and the
advancement and potential of Arena's clinical programs and
collaborations. For such statements, Arena claims the protection of
the Private Securities Litigation Reform Act of 1995. Actual events
or results may differ materially from Arena's expectations. Factors
that could cause actual results to differ materially from the
forward-looking statements include, but are not limited to, the
following: the risk that the cost and other negative effects
related to the reduction of Arena's workforce may be greater than
anticipated; the risk that Arena may not realize the benefits
expected from the workforce reduction or other cost control
measures; risks related to developing and commercializing drugs;
the risk that we may need additional funds to advance all of our
programs, and you and others may not agree with the manner we
allocate our resources; cash and revenues generated from BELVIQ,
including the impact of competition; the risk that Arena's revenues
are based in part on estimates, judgment and accounting policies,
and incorrect estimates or disagreement regarding estimates or
accounting policies may result in changes to Arena's guidance or
previously reported results; the timing and outcome of regulatory
review is uncertain, and lorcaserin may not be approved for
marketing in a different formulation or in any other territory;
regulatory decisions in one territory may impact other regulatory
decisions and Arena's business prospects; government and commercial
reimbursement and pricing decisions; risks related to relying on
collaborative arrangements; the timing and receipt of payments and
fees, if any, from collaborators; the entry into or modification or
termination of collaborative arrangements; unexpected or
unfavorable new data; nonclinical and clinical data is voluminous
and detailed, and regulatory agencies may interpret or weigh the
importance of data differently and reach different conclusions than
Arena or others, request additional information, have additional
recommendations or change their guidance or requirements before or
after approval; data and other information related to any of
Arena's research and development may not meet regulatory
requirements or otherwise be sufficient for (or Arena or a
collaborator may not pursue) further research and development,
regulatory review or approval or continued marketing; Arena's and
third parties' intellectual property rights; the timing, success
and cost of Arena's research and development and related strategy
and decisions; results of clinical trials and other studies are
subject to different interpretations and may not be predictive of
future results; clinical trials and other studies may not proceed
at the time or in the manner expected or at all; having adequate
funds; and satisfactory resolution of litigation or other
disagreements with others. Additional factors that could cause
actual results to differ materially from those stated or implied by
Arena's forward-looking statements are disclosed in Arena's filings
with the Securities and Exchange Commission. These forward-looking
statements represent Arena's judgment as of the time of this
release. Arena disclaims any intent or obligation to update these
forward-looking statements, other than as may be required under
applicable law.
Contact:
Kevin R. Lind,
Chief Financial Officer
klind@arenapharm.com
858.453.7200 x1716
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/arena-pharmaceuticals-to-release-second-quarter-2016-financial-results-and-provide-corporate-update-on-monday-august-8-2016-300307030.html
SOURCE Arena Pharmaceuticals, Inc.